Moderna shares surge about 90% after reported late-stage melanoma vaccine trial result, as Merck also rises

Moderna’s stock jumped dramatically on Wednesday after a report highlighted strong late-stage results for a cancer vaccine in melanoma patients. According to market coverage, the reaction was immediate and outsized, with Moderna shares surging by about 90%. The move also carried over to Merck, where shares rose as investors appeared to connect the news to the companies’ broader oncology collaboration and vaccine-area exposure.

Merck’s stock gain alongside Moderna’s suggests the market viewed the late-stage outcome as relevant beyond a single-company headline. Still, the information available from the market post does not detail the strength of the clinical findings, the size of the patient population, or the specific endpoints used to judge success, such as overall survival or progression-free survival.

The report framed the catalyst as a “trial win” for Moderna’s cancer vaccine program. It described the development as late-stage and tied to melanoma, a skin cancer with high visibility in drug development because of its prevalence and historically difficult treatment landscape once it progresses.

Moderna is known for developing messenger RNA (mRNA) medicines, a technology that uses genetic instructions to prompt the body to produce a target protein or immune announcement. In oncology, that approach is often aimed at training the immune system to recognize cancer-associated targets. Late-stage readouts are typically where investors look for confirmatory evidence, since earlier-phase results can be too preliminary to support regulatory filing or broad adoption.

While Wednesday’s market reaction was large, the market post does not provide granular trial information. It does not state the magnitude of benefit versus a comparator, report safety rates or adverse events, or clarify whether the result met a primary endpoint. It also does not say whether the trial involved a standalone regimen or a combination strategy, or whether patients were previously treated.

Merck’s participation is notable because the company has long been active in oncology and has pursued multiple partnerships that can include vaccine approaches, immune-oncology therapies, and other modalities that aim to improve response durability. However, the post that drove the share moves does not lay out which specific Moderna program Merck’s investors were trading on, or how the companies’ roles map to the melanoma trial in question.

In the absence of more detailed disclosures, the most immediate takeaway is about how markets treat late-stage clinical indicates in biotech, especially when they involve high-risk therapeutic areas like cancer vaccines. Even before regulators or medical communities review the data, trading can reflect expectations for future filings and potential commercial impact if the results hold up and are fully reported.

Investors and clinicians will likely watch for the next formal step: a full data release, typically through a regulatory submission or a peer-reviewed presentation, along with clearer reporting on efficacy endpoints, safety, and study design. Until then, questions remain about how broadly the findings apply, how durable the responses may be, and whether the benefit profile is strong enough to change treatment practice in melanoma.